Survival outcomes of management in metastatic gastric adenocarcinoma patients

Abstract Chemotherapy is generally considered as the main treatment for metastatic gastric adenocarcinoma. The role of gastrectomy for metastatic gastric cancer without obvious symptoms is controversial. The objective of this study is to investigate survival outcomes of treatment modalities using a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Huang-Ming Hu, Hui-Jen Tsai, Hsiu-Ying Ku, Su-Shun Lo, Yan-Shen Shan, Hung-Chi Chang, Yee Chao, Jen-Shi Chen, Shu-Chen Chen, Chun-Ju Chiang, Anna Fen-Yau Li, Hsiu-Po Wang, Tsang-En Wang, Li-Yuan Bai, Ming-Shiang Wu, Li-Tzong Chen, Tsang-Wu Liu, Yi-Hsin Yang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6d79e1ee763b4d4a95259e0871837120
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6d79e1ee763b4d4a95259e0871837120
record_format	dspace
spelling	oai:doaj.org-article:6d79e1ee763b4d4a95259e08718371202021-12-05T12:15:23ZSurvival outcomes of management in metastatic gastric adenocarcinoma patients10.1038/s41598-021-02391-z2045-2322https://doaj.org/article/6d79e1ee763b4d4a95259e08718371202021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-02391-zhttps://doaj.org/toc/2045-2322Abstract Chemotherapy is generally considered as the main treatment for metastatic gastric adenocarcinoma. The role of gastrectomy for metastatic gastric cancer without obvious symptoms is controversial. The objective of this study is to investigate survival outcomes of treatment modalities using a real-world data setting. A retrospective cohort study was designed using the Taiwan Cancer Registry database. We identified the treatment modalities and used Kaplan–Meier estimates and Cox regressions to compare patient survival outcomes. From 2008 to 2015, 5599 gastric adenocarcinoma patients were diagnosed with metastatic disease (M1). The median overall survival (OS) of patients with surgery plus chemotherapy had the longest survival of 14.2 months. The median OS of the patients who received chemotherapy alone or surgery alone was 7.0 and 3.9, respectively. Age at diagnosis, year of diagnosis, tumor grade, and treatment modalities are prognostic factors for survival. The hazard ratios for patients who received surgery plus chemotherapy, surgery alone, and supportive care were 0.47 (95% CI 0.44–0.51), 1.22 (95% CI 1.1–1.36), and 3.23 (95% CI 3.01–3.46), respectively, by multivariable Cox regression analysis when using chemotherapy alone as a referent. Chemotherapy plus surgery may have a survival benefit for some selected gastric adenocarcinoma patients with metastatic disease.Huang-Ming HuHui-Jen TsaiHsiu-Ying KuSu-Shun LoYan-Shen ShanHung-Chi ChangYee ChaoJen-Shi ChenShu-Chen ChenChun-Ju ChiangAnna Fen-Yau LiHsiu-Po WangTsang-En WangLi-Yuan BaiMing-Shiang WuLi-Tzong ChenTsang-Wu LiuYi-Hsin YangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Huang-Ming Hu Hui-Jen Tsai Hsiu-Ying Ku Su-Shun Lo Yan-Shen Shan Hung-Chi Chang Yee Chao Jen-Shi Chen Shu-Chen Chen Chun-Ju Chiang Anna Fen-Yau Li Hsiu-Po Wang Tsang-En Wang Li-Yuan Bai Ming-Shiang Wu Li-Tzong Chen Tsang-Wu Liu Yi-Hsin Yang Survival outcomes of management in metastatic gastric adenocarcinoma patients
description	Abstract Chemotherapy is generally considered as the main treatment for metastatic gastric adenocarcinoma. The role of gastrectomy for metastatic gastric cancer without obvious symptoms is controversial. The objective of this study is to investigate survival outcomes of treatment modalities using a real-world data setting. A retrospective cohort study was designed using the Taiwan Cancer Registry database. We identified the treatment modalities and used Kaplan–Meier estimates and Cox regressions to compare patient survival outcomes. From 2008 to 2015, 5599 gastric adenocarcinoma patients were diagnosed with metastatic disease (M1). The median overall survival (OS) of patients with surgery plus chemotherapy had the longest survival of 14.2 months. The median OS of the patients who received chemotherapy alone or surgery alone was 7.0 and 3.9, respectively. Age at diagnosis, year of diagnosis, tumor grade, and treatment modalities are prognostic factors for survival. The hazard ratios for patients who received surgery plus chemotherapy, surgery alone, and supportive care were 0.47 (95% CI 0.44–0.51), 1.22 (95% CI 1.1–1.36), and 3.23 (95% CI 3.01–3.46), respectively, by multivariable Cox regression analysis when using chemotherapy alone as a referent. Chemotherapy plus surgery may have a survival benefit for some selected gastric adenocarcinoma patients with metastatic disease.
format	article
author	Huang-Ming Hu Hui-Jen Tsai Hsiu-Ying Ku Su-Shun Lo Yan-Shen Shan Hung-Chi Chang Yee Chao Jen-Shi Chen Shu-Chen Chen Chun-Ju Chiang Anna Fen-Yau Li Hsiu-Po Wang Tsang-En Wang Li-Yuan Bai Ming-Shiang Wu Li-Tzong Chen Tsang-Wu Liu Yi-Hsin Yang
author_facet	Huang-Ming Hu Hui-Jen Tsai Hsiu-Ying Ku Su-Shun Lo Yan-Shen Shan Hung-Chi Chang Yee Chao Jen-Shi Chen Shu-Chen Chen Chun-Ju Chiang Anna Fen-Yau Li Hsiu-Po Wang Tsang-En Wang Li-Yuan Bai Ming-Shiang Wu Li-Tzong Chen Tsang-Wu Liu Yi-Hsin Yang
author_sort	Huang-Ming Hu
title	Survival outcomes of management in metastatic gastric adenocarcinoma patients
title_short	Survival outcomes of management in metastatic gastric adenocarcinoma patients
title_full	Survival outcomes of management in metastatic gastric adenocarcinoma patients
title_fullStr	Survival outcomes of management in metastatic gastric adenocarcinoma patients
title_full_unstemmed	Survival outcomes of management in metastatic gastric adenocarcinoma patients
title_sort	survival outcomes of management in metastatic gastric adenocarcinoma patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/6d79e1ee763b4d4a95259e0871837120
work_keys_str_mv	AT huangminghu survivaloutcomesofmanagementinmetastaticgastricadenocarcinomapatients AT huijentsai survivaloutcomesofmanagementinmetastaticgastricadenocarcinomapatients AT hsiuyingku survivaloutcomesofmanagementinmetastaticgastricadenocarcinomapatients AT sushunlo survivaloutcomesofmanagementinmetastaticgastricadenocarcinomapatients AT yanshenshan survivaloutcomesofmanagementinmetastaticgastricadenocarcinomapatients AT hungchichang survivaloutcomesofmanagementinmetastaticgastricadenocarcinomapatients AT yeechao survivaloutcomesofmanagementinmetastaticgastricadenocarcinomapatients AT jenshichen survivaloutcomesofmanagementinmetastaticgastricadenocarcinomapatients AT shuchenchen survivaloutcomesofmanagementinmetastaticgastricadenocarcinomapatients AT chunjuchiang survivaloutcomesofmanagementinmetastaticgastricadenocarcinomapatients AT annafenyauli survivaloutcomesofmanagementinmetastaticgastricadenocarcinomapatients AT hsiupowang survivaloutcomesofmanagementinmetastaticgastricadenocarcinomapatients AT tsangenwang survivaloutcomesofmanagementinmetastaticgastricadenocarcinomapatients AT liyuanbai survivaloutcomesofmanagementinmetastaticgastricadenocarcinomapatients AT mingshiangwu survivaloutcomesofmanagementinmetastaticgastricadenocarcinomapatients AT litzongchen survivaloutcomesofmanagementinmetastaticgastricadenocarcinomapatients AT tsangwuliu survivaloutcomesofmanagementinmetastaticgastricadenocarcinomapatients AT yihsinyang survivaloutcomesofmanagementinmetastaticgastricadenocarcinomapatients
_version_	1718372078390870016

Survival outcomes of management in metastatic gastric adenocarcinoma patients

Ejemplares similares